Korian is an actor on the temporary and permanent dependency care market in France, Germany and Italy. Co. offers and develops services related to dependency through its retirement homes (116 as of Dec 31 2009), follow-up care and rehabilitation facilities (35 as of Dec 31 2009) and psychiatric clinics (11 as of Dec 31 2009). Co.'s operations can be divided into four geographical segments: Medical and Social activity in France (retirement homes); Sanitary activity in France (follow-up care, rehabilitation, psychiatry and home medical care); Italy; and Germany.
  • TickerKORI
  • ISINFR0010386334
  • ExchangeEuronext Paris
  • SectorHealth Care Equipment & Services
  • CountryFrance

Analysts

Antoine Boivin-Champeaux ...
  • Charles Lepetitpas
  • Christophe Chaput
  • Christophe-Raphaël Ganet
  • Fatma Agnès Hamdani
  • Florent Laroche-Joubert
  • Geoffroy Michalet
  • Hela Zarrouk
  • Jeremy Garnier
  • Jerôme Bodin
  • Laurence Hofmann
  • Nicolas David
  • Salma Bouraoui
  • Yan Derocles

ODDO BHF Small & MIDCAP MORNING NEWS - 15/03/2019

...

Christophe-Raphaël Ganet

Korian : Résultats 2018 conformes (bon ramp-up hors de France) - Guidances moyen terme updatées : visibilité et statut boursier renforcés

>EBITDA et ROC en ligne avec nos attentes - L’EBITDAR 2018 ressort à 873 M€ (contre 869 M€ attendus), L’EBITDA 2018 ressort à 477 M€ (+8,4%), le ROP à 299 M€ (+5,6%), et le BN, à 123 M€ (-24,6%). La dette nette, y compris immobilier, s’établit à 2 723 M€ (+383 M€, +16%). La dette financière nette, hors dette immobilière, reste stable à 1 207 M€ (contre 1 209 M€ à fin 2017). Korian propose une guidance 2019 de CA à (+8% (soit env. >3 600 Md€e) et une marge d’EBITDA (14...

KORIAN SA sees an upgrade to Slightly Positive due to a better fundamental star rating

The general evaluation of KORIAN SA (FR), a company active in the Health Care Providers industry, has been upgraded by the independent financial analyst theScreener with the addition of a star. Its fundamental valuation now shows 4 out of 4 possible stars while its market behaviour can be considered as moderately risky. theScreener believes that the additional star(s) merits the upgrade of its general evaluation to Slightly Positive. As of the analysis date March 1, 2019, the closing price was EUR 33.00 and its potential was estimated at EUR 37.11.

Korian - Assemblée générale des actionnaires du 06 juin 2019

Proxinvest publiera une étude analysant les résolutions proposées lors de la tenue de l’assemblée générale des actionnaires. Vous pouvez l'acquérir dès à présent et elle vous sera adressée par ResearchPool une fois publiée.

Bruno de La Rochebrochard

Korian: Q2 revenue: further improvement in organic growth continues with dynamic bolt-on acquisitions

Brief Comment - Korian: (BUY, Fair Value EUR33 (+12%)) Q2 revenue: further improvement in organic growth continues with dynamic bolt-on acquisitions

Tony Lebon

Korian : Potential takeover bid on Korian: implications for ODIRNANE bond holders

Tony Lebon

Korian : Potential takeover bid on Korian: implications for ODIRNANE bond holders

Christophe-Raphaël Ganet

Korian : Résultats 2018 conformes (bon ramp-up hors de France) - Guidances moyen terme updatées : visibilité et statut boursier renforcés

>EBITDA et ROC en ligne avec nos attentes - L’EBITDAR 2018 ressort à 873 M€ (contre 869 M€ attendus), L’EBITDA 2018 ressort à 477 M€ (+8,4%), le ROP à 299 M€ (+5,6%), et le BN, à 123 M€ (-24,6%). La dette nette, y compris immobilier, s’établit à 2 723 M€ (+383 M€, +16%). La dette financière nette, hors dette immobilière, reste stable à 1 207 M€ (contre 1 209 M€ à fin 2017). Korian propose une guidance 2019 de CA à (+8% (soit env. >3 600 Md€e) et une marge d’EBITDA (14...

Christophe-Raphaël Ganet

Korian : Good Q4 sales - EBITDA margin up from 14% to 14.3% - Momentum maintained - Buy reiterated

>Q4: +3% l-f-l - Scope effect and acceleration in org. growth in France - Q4 sales were up to € 863m (+7.6% and +3.3% l-f-l) of which € 91m in Italy (vs € 93m est.), € 233m in Germany (€ 231m est.), € 416m in France (vs € 408.5m) and € 123m in Belgium (vs € 119m est.). For the full year, sales were € 3,336m, i.e. +6.4% and +3% l-f-l, with 3,100 new beds in operation. Korian indicates that it is targeting an EBITDA margin of 14.3% (vs 14% in 2017) vs 14% in the previou...

Bruno de La Rochebrochard

KORIAN: Feed back CC FY revenue: Above consensus and FY guidance upgraded | BUY | EUR38

KORIAN - BUY | EUR38(+23%) Feed back CC FY revenue: Above consensus and FY guidance upgraded Sustained organic revenue growth above expectation… …and FY guidance upgraded Positive outlook confirmed even if no precise numbers will be given before FY results

Christophe-Raphaël Ganet

Korian : Bon CA T4 – Marge d’EBITDA relevée de 14% à 14,3% – Momemtum bien entretenu – Achat maintenu

>T4 : +3% lfl. - Effet périmètre et accélération de l’organique en France - Les revenus du T4 se sont montés à 863 M€ (+7,6% et +3.3% lfl.) dont Italie, 91 M€ (vs 93 M€e), Allemagne, 233 M€ (231 M€e), France, 416 M€ (vs 408.5M€) et Belgique, 123 M€ (vs 119 M€e).En année pleine, le CA atteint 3 336 M€, soit +6.4% et +3% lfl. avec 3 100 nouveaux lits exploités.Korian indique viser une marge d’EBITDA de 14.3% (vs 14% en 2017) contre 14% précédemment guidé (meil...

Bruno de La Rochebrochard

KORIAN: Waiting for FY revenue and guidance that should be upgraded | BUY | EUR38

KORIAN - BUY | EUR38(+25%) Waiting for FY revenue and guidance that should be upgraded FY revenue that should be in line with expectation… ….but short and medium term guidance should be upgraded

1 director bought

A director at Korian Promesses bought 4,821 shares at 29.261EUR and the significance rating of the trade was 65/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names...

Antoine Boivin-Champeaux ...
  • Charles Lepetitpas
  • Christophe Chaput
  • Christophe-Raphaël Ganet
  • Fatma Agnès Hamdani
  • Florent Laroche-Joubert
  • Geoffroy Michalet
  • Hela Zarrouk
  • Jeremy Garnier
  • Jerôme Bodin
  • Laurence Hofmann
  • Nicolas David
  • Salma Bouraoui
  • Yan Derocles

ODDO BHF Small & MIDCAP MORNING NEWS - 15/03/2019

...

Alain William ...
  • Benoit Valleaux
  • Christophe Chaput
  • Christophe-Raphaël Ganet
  • Geoffroy Michalet
  • Jean-François Granjon
  • Jeremy Garnier
  • Michael Foundoukidis
  • Nicolas Thorez
  • Roland Pfaender

ODDO BHF Small & MIDCAP MORNING NEWS - 02/06/2019 Date Performance since listing Date Performance since listing

...

Alain William ...
  • Benoit Valleaux
  • Christophe Chaput
  • Christophe-Raphaël Ganet
  • Geoffroy Michalet
  • Jean-François Granjon
  • Jeremy Garnier
  • Michael Foundoukidis
  • Nicolas Thorez
  • Roland Pfaender

ODDO BHF Small & MIDCAP MORNING NEWS - 06/02/2019 Date Performance depuis l’entrée Date Performance depuis l’entrée

...

Christophe Chaput ...
  • Christophe-Raphaël Ganet
  • Jeremy Garnier
  • Nicolas Thorez

ODDO BHF Small & MIDCAP MORNING NEWS - 01/10/2019

...

Christophe Chaput ...
  • Christophe-Raphaël Ganet
  • Jeremy Garnier
  • Nicolas Thorez

ODDO BHF Small & MIDCAP MORNING NEWS - 10/01/2019

...

KORIAN SA sees an upgrade to Slightly Positive due to a better fundamental star rating

The general evaluation of KORIAN SA (FR), a company active in the Health Care Providers industry, has been upgraded by the independent financial analyst theScreener with the addition of a star. Its fundamental valuation now shows 4 out of 4 possible stars while its market behaviour can be considered as moderately risky. theScreener believes that the additional star(s) merits the upgrade of its general evaluation to Slightly Positive. As of the analysis date March 1, 2019, the closing price was EUR 33.00 and its potential was estimated at EUR 37.11.

Ford Equity International Rating and Forecast Report

Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the week...

Korian - Assemblée générale des actionnaires du 06 juin 2019

Proxinvest publiera une étude analysant les résolutions proposées lors de la tenue de l’assemblée générale des actionnaires. Vous pouvez l'acquérir dès à présent et elle vous sera adressée par ResearchPool une fois publiée.

Jehanne Leroy

Proxy Report - 14/06/2018

La politique de rémunération de Mme Boissard souffre toujours d’une faiblesse significative : la rémunération actionnariale soit basée sur des conditions de performance qui ne sont pas mesurées sur le long-terme (3 ans minimum). Cependant, la société a mis en place pour la politique de rémunération 2018 2 améliorations significatives concernant le plafonnement de la rémunération long-terme et celui des rémunérations exceptionnelles. Aussi la politique de rémunération 2018 semble préférable à celle mise en place pour 2017 et nous soutenons donc la nouvelle politique (résolution 7). Cependant, ...

Matthieu DRIOL

Analyse court terme - KORIAN : La tendance de fond est clairement orientée à la hausse.

La tendance de fond est clairement orientée à la hausse. Les cours progressent toujours. Les objectifs suivants sont à 34,74 € et 35,50 €. La tendance serait invalidée sous le support à 27,30 €.

Matthieu DRIOL

Short term view - KORIAN : The background trend is clearly bullish.

The background trend is clearly bullish. Prices are still making progress. The following targets are at €34.74 and €35.50. The trend would be invalidated below the support at €27.30.

Matthieu DRIOL

Short term view - KORIAN : Prices are still making progress.

The background trend is clearly bullish. Prices are still making progress. The following targets are at €34.74 and €35.50. The trend would be invalidated below the support at €27.30.

Matthieu DRIOL

Analyse court terme - KORIAN : Les cours progressent toujours.

La tendance de fond est clairement orientée à la hausse. Les cours progressent toujours. Les objectifs suivants sont à 34,74 € et 35,50 €. La tendance serait invalidée sous le support à 27,30 €.

Matthieu DRIOL

Medium term view - KORIAN : Prices are still making progress.

The background trend is clearly bullish. Prices are still making progress. The following targets are at €37.00 and €41.61. The trend would be invalidated below the support at €27.64.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch